A Phase I, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmakinetics of PTI-428 in Subjects With Cystic Fibrosis.
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2018
At a glance
- Drugs PTI 428 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Proteostasis Therapeutics
- 13 Apr 2018 Planned End Date changed from 1 Nov 2017 to 1 Dec 2018.
- 13 Apr 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2018.
- 28 Aug 2017 New trial record